Drugs / JTT-251
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02106585 | Mar → Aug 2014 | diabetes mellitus | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03789643 | Mar 2019 → Mar 2021 | pulmonary arterial hypertension | Akros Pharma Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTT-251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03789643 ↗ |
| Modality | Small molecule | — CHEMBL3673096 ↗ |
| Route | Oral | “single oral doses of JTT-251” NCT02106585 ↗ |